Adnan Tufail, MD, FRCOphth
Dr. Tufail is one of the leading ophthalmic surgeons in the UK and is the clinical and research lead at Moorfields Eye Hospital in London for age-related macular degeneration. He has worked as a consultant at Moorfields Eye Hospital since 2002 and is an Honorary Senior Lecturer at University College London Institute of Ophthalmology.
Dr. Tufail’s main subspecialty interest is medical retina disorders. His current area of research interest includes novel therapies for dry AMD, choroidal neovascularization and diabetic retinopathy. Dr. Tufail has published more than 80 peer-reviewed journal articles. Most notably, he was a co-principal investigator in the seminal ABC Trial examining bevacizumab for neovascular age related macular degeneration. The ABC Trial became a cornerstone for anti-VEGF treatment protocols for wet-AMD therapy within the National Health Service (NHS).
Dr. Tufail completed his fellowship in medical retina at Moorfields Eye Hospital and undertook further studies at Vanderbilt Medical Centre, Nashville, Tennessee. Dr. Tufail spent an additional two and a half years training in uveitis at the Jules Stein Eye Hospital, Los Angeles, California, and completed a higher research degree during that time. He received his medical training from Guy’s Hospital Medical School at the University of London.
Dr. Tufail is a fellow of the Royal College of Ophthalmologist and a member of The American Society of Retina Specialists. He is also a member of the European Vision Institute Retina Panel.